Intellia Therapeutics (NTLA) News Today $9.66 +0.34 (+3.65%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$7.42 -2.24 (-23.20%) As of 09:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NTLA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Purchased by Polar Asset Management Partners Inc.Polar Asset Management Partners Inc. boosted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 1,144.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 282,400 shares of the compMay 28 at 5:52 AM | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Purchased by Millennium Management LLCMillennium Management LLC raised its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 190.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 668,926 shares of the companyMay 28 at 3:43 AM | marketbeat.comBank of America Corp DE Trims Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Bank of America Corp DE cut its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 10.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 639,696 shares of the company's stock after selling 76,495 shares dMay 27 at 3:14 AM | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Trading Down 4.3% - Time to Sell?Intellia Therapeutics (NASDAQ:NTLA) Stock Price Down 4.3% - Time to Sell?May 25, 2025 | marketbeat.comVoloridge Investment Management LLC Acquires 1,059,751 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)Voloridge Investment Management LLC grew its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 226.8% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,526,994 shares of the company's stock after buying an additional 1,059,751 shares durMay 25, 2025 | marketbeat.comTwo Sigma Investments LP Has $21.50 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Two Sigma Investments LP raised its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 88.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,843,743 shares of the company's stock after purcMay 24, 2025 | marketbeat.comDeutsche Bank AG Raises Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Deutsche Bank AG boosted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 12.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 252,501 shares of the company's stock after purchasing an additional 27,282 shares duringMay 24, 2025 | marketbeat.comAnalysts Think These Stocks Could More Than Double in Value (NTLA)Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.May 23, 2025 | marketbeat.comTwo Sigma Advisers LP Acquires 970,700 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)Two Sigma Advisers LP boosted its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 94.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,998,317 shares of the company's stock after buying an aMay 23, 2025 | marketbeat.comIntellia Therapeutics' (NTLA) "Buy" Rating Reiterated at HC WainwrightMay 23, 2025 | americanbankingnews.comINTELLIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmMay 22, 2025 | globenewswire.comIntellia Therapeutics (NASDAQ:NTLA) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of Intellia Therapeutics in a research note on Tuesday.May 22, 2025 | marketbeat.comVestal Point Capital LP Makes New $6.12 Million Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Vestal Point Capital LP acquired a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 525,000 shares of the company's stMay 21, 2025 | marketbeat.comTema Etfs LLC Makes New Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Tema Etfs LLC purchased a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 148,167 shares of the company's stock, valued at approximately $1,May 20, 2025 | marketbeat.comIntellia Therapeutics' (NTLA) Neutral Rating Reiterated at WedbushMay 20, 2025 | americanbankingnews.comSecond Line Capital LLC Takes Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Second Line Capital LLC purchased a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 131,122 shares of the coMay 19, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Northern Trust CorpNorthern Trust Corp grew its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 13.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 979,137 shares of the company's stock after acquiring an additional 112,847 shares during the qMay 19, 2025 | marketbeat.comIntellia Therapeutics announces two-year follow-up data from trial of nex-zMay 18, 2025 | msn.comIntellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual MeetingMay 18, 2025 | globenewswire.comSphera Funds Management LTD. Grows Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Sphera Funds Management LTD. grew its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 60.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 466,080 shares of thMay 18, 2025 | marketbeat.comPolar Asset Management Partners Inc. Boosts Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Polar Asset Management Partners Inc. boosted its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 1,144.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 282,400 shares of the company'sMay 18, 2025 | marketbeat.comCathie Wood’s ARK Buys Intellia, Nextdoor, Sells Block StockMay 17, 2025 | investing.comPatient Square Capital LP Increases Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Patient Square Capital LP increased its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 68.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 215,981 sharesMay 16, 2025 | marketbeat.comFY2025 EPS Estimates for NTLA Lifted by Cantor FitzgeraldIntellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Cantor Fitzgerald upped their FY2025 earnings per share estimates for shares of Intellia Therapeutics in a research note issued to investors on Monday, May 12th. Cantor Fitzgerald analyst R. Bienkowski now expects that the company will earMay 16, 2025 | marketbeat.comBNP Paribas Financial Markets Has $5.11 Million Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)BNP Paribas Financial Markets increased its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 78.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 438,458 shares of the company's sMay 16, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Holdings Decreased by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD reduced its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 93.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 39,295 shares of thMay 16, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Purchased by Hudson Bay Capital Management LPHudson Bay Capital Management LP boosted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 52.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 512,300 shares of the company's stMay 15, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)May 14, 2025 | seekingalpha.comEvercore ISI Remains a Buy on Intellia Therapeutics (NTLA)May 14, 2025 | theglobeandmail.comTruist Financial Keeps Their Buy Rating on Intellia Therapeutics (NTLA)May 14, 2025 | theglobeandmail.comGuggenheim Lowers Intellia Therapeutics (NASDAQ:NTLA) Price Target to $45.00Guggenheim lowered their price objective on shares of Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating for the company in a research note on Monday.May 14, 2025 | marketbeat.comForecasting The Future: 11 Analyst Projections For Intellia TherapeuticsMay 13, 2025 | benzinga.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesIntellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twenty research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have issued a hold rMay 12, 2025 | marketbeat.comAnalyst Estimates: Here's What Brokers Think Of Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its First-Quarter ReportMay 11, 2025 | finance.yahoo.comIntellia Therapeutics (NASDAQ:NTLA) Receives Buy Rating from Chardan CapitalChardan Capital reiterated a "buy" rating and issued a $68.00 price objective on shares of Intellia Therapeutics in a research note on Friday.May 11, 2025 | marketbeat.comNews Flash: Analysts Just Made An Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) ForecastsMay 10, 2025 | finance.yahoo.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by Brevan Howard Capital Management LPBrevan Howard Capital Management LP increased its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 626.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor ownedMay 10, 2025 | marketbeat.comIntellia Therapeutics Inc (NTLA) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ...May 10, 2025 | finance.yahoo.comIntellia Therapeutics, Inc.: Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company ProgressMay 9, 2025 | finanznachrichten.deIntellia therapeutics outlines 2026 BLA filing for NTLA-2002 in HAE amid strong Phase 3 progressMay 9, 2025 | msn.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Position Increased by Dimensional Fund Advisors LPDimensional Fund Advisors LP lifted its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 36.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,976,212 shares oMay 9, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comIntellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company ProgressMay 8, 2025 | finance.yahoo.comCapstone Investment Advisors LLC Grows Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Capstone Investment Advisors LLC increased its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 77.8% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 108,665 shares of the company's stock after purchasing anMay 8, 2025 | marketbeat.comAptus Capital Advisors LLC Takes $1.62 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Aptus Capital Advisors LLC acquired a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 139,278 shares of the company's stock, valued at approximately $1,624May 8, 2025 | marketbeat.com2NTLA : A Glimpse of Intellia Therapeutics's Earnings PotentialMay 7, 2025 | benzinga.comIntellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 6, 2025 | globenewswire.comBaker BROS. Advisors LP Purchases New Shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Baker BROS. Advisors LP bought a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 644,116 shares of the company's stock, valued at aMay 6, 2025 | marketbeat.comIntellia Therapeutics (NTLA) Expected to Announce Earnings on ThursdayIntellia Therapeutics (NASDAQ:NTLA) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-intellia-therapeutics-inc-stock/)May 3, 2025 | marketbeat.comStifel Financial Corp Buys 303,151 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)Stifel Financial Corp raised its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 320.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 397,761 shares of the company'sMay 3, 2025 | marketbeat.com Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address NTLA Media Mentions By Week NTLA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NTLA News Sentiment▼1.080.87▲Average Medical News Sentiment NTLA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NTLA Articles This Week▼1312▲NTLA Articles Average Week Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Sarepta Therapeutics News Akero Therapeutics News Avidity Biosciences News ACADIA Pharmaceuticals News Cytokinetics News PTC Therapeutics News Krystal Biotech News Arcellx News SpringWorks Therapeutics News Zai Lab News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NTLA) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NTLA Stock Free NTLA Stock Alerts